Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2023-02-08
- Target Recruit Count
- 288
- Registration Number
- NCT05717790
- Locations
- 🇨🇳
Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi, China
🇨🇳Guilin Medical University, China, Guilin, Guangxi, China
🇨🇳Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, Guangxi, China
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-02-03
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Lisata Therapeutics, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT05712356
- Locations
- 🇪🇸
Hospital Universitario de Vinalopó, Elche, Alicante, Spain
🇪🇸Hospital Universitario de Jerez, Jerez De La Frontera, Cadiz, Spain
🇪🇸Start Madrid - Hospital Universitario HM Sanchinarro, Madrid, Spain
Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Zhujiang Hospital
- Target Recruit Count
- 144
- Registration Number
- NCT05701436
- Locations
- 🇨🇳
Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
- Conditions
- Interventions
- First Posted Date
- 2023-01-20
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1122
- Registration Number
- NCT05691478
- Locations
- 🇺🇸
Newark Beth Israel Medical Center, Newark, New Jersey, United States
🇺🇸State University of New York Upstate Medical University, Syracuse, New York, United States
🇺🇸Alfred I duPont Hospital for Children, Wilmington, Delaware, United States
Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-01-19
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Nikolaj Frost MD
- Target Recruit Count
- 136
- Registration Number
- NCT05689671
- Locations
- 🇩🇪
LungenClinic Großhansdorf GmbH, Großhansdorf, Germany
🇩🇪Universitätsmedizin Göttingen, Göttingen, Germany
🇩🇪Asklepios Klinkum Hamburg, Hamburg, Germany
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
- Conditions
- Interventions
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1350
- Registration Number
- NCT05687266
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Radiotherapy Alone Versus Concurrent Chemo-radiotherapy for Nasopharyngeal Carcincoma Patients With Undectable EBV DNA After One Cylce Neoadjuvant Chemotherpy
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 366
- Registration Number
- NCT05674305
- Locations
- 🇨🇳
Fudan Universtiy Shanghai Cancer Centre, Shanghai, Shanghai, China
Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk
- Conditions
- Interventions
- First Posted Date
- 2023-01-05
- Last Posted Date
- 2023-01-05
- Target Recruit Count
- 70
- Registration Number
- NCT05672537
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Treatment of Advance Gastric Cancer With Disulfiram
- Conditions
- Interventions
- First Posted Date
- 2022-12-28
- Last Posted Date
- 2022-12-28
- Lead Sponsor
- First People's Hospital of Hangzhou
- Target Recruit Count
- 40
- Registration Number
- NCT05667415
- Locations
- 🇨🇳
Hangzhou first people's Hospital, Hangzhou, Zhejiang, China
JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT05664971
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.